Company History
2008
March
HTG receives a Phase I SBIR grant for $300k to develop a microfluidics diagnostic qNPA platform to monitor white blood cell response.
January
TJ Johnson joins HTG as CEO and President.
2007
HTG and the University of Arizona Bio5 Center for Chemical Genomics and Translational Research receive $2M seed funding from Science Foundation Arizona.
December
Jonathan Sheridan joins HTG as VP Commercial Operations.
September
HTG receives a Phase I SBIR grant for $300k to develop a 1600 gene high density qNPA™ array from NIMH.
2006
Bill Radney joins HTG as CEO and President
2005
December
Don Grimm joins HTG’s Board of Directors. Company records its second profitable operating quarter.
September
HTG records its first profitable operating quarter.
July
HTG purchases print and hybridization acceleration IP from Sigma Aldrich.
April
Company completes its “Series B” round of financing.
February
HTG adds two internationally esteemed researchers to its Scientific Advisory Board, contracting the services of Raymond L. Woosley, M.D., Ph.D. and Daniel D. Von Hoff, MD.
2004
September
Services agreements reached with Takeda Pharmaceutical Company, Ltd. to support Takeda’s pharmaceutical research.
August
Kirk Collamer assumes positions of company President and CEO.
Bruce Seligmann assumes position of CSO and Chairman of the Board
April
Merck & Co., Inc. licenses HTG’s gene expression assay technology worldwide.
February
National Cancer Institute awards HTG a two-year grant to identify genes for toxicity studies.
2003
August
William Linton, founder of Promega Corporation, joins HTG’s Board of Directors.
2002
November
Third U.S. patent issued
April
Kirk Collamer joins HTG as Chief Financial Officer.
January
Completed “Series A” preferred round of company financing. Purchased Genometrix Universal Array IP and tangible assets. First Omix Imaging System sold and HTS assay contract. Client: Psychiatric Genomics, Inc.
2001
October
First service contract. Client: Signal Research, division of Celgene Corporation
July
HTG introduced its first commercial product, the ArrayPlate™ 96-16.
May
First Generic Array and qNPA patents issued.
March
Completed Founders round of investment.
January
HTG was divested from SIDDCO. Generic Array and quantitative Nuclease Protection Array (qNPA) IP was purchased from NeoGen, Inc.
2000
December
HTG was divested to SIDDCO’s shareholders prior to its sale to Discovery Partners international, Inc. At the time of divestiture, HTG’s intellectual portfolio included license rights to Generic Array and qNPA technology, invented by NeoGen L.L.C.
Bruce Seligmann, founder, assumes President and CEO positions
1997
High Throughput Genomics, Inc, (HTG) was established as a wholly owned subsidiary of Systems Integration Drug Discovery Company (SIDDCO), a privately held combinatorial chemistry company.
